What is the appropriate cyclosporine regimen for a 70‑kg adult with psoriasis, including starting dose, titration, monitoring parameters, contraindications, and alternative treatment options?

Cyclosporine for Psoriasis: Dosing and Management Protocol

Starting Dose and Titration

For a 70-kg adult with psoriasis, start cyclosporine at 2.5 mg/kg/day (175 mg/day) divided into two doses, taken before meals. 1 This initial conservative approach balances efficacy with safety, particularly important given the patient's age and potential comorbidities.

Dose Escalation Strategy

• Maintain the starting dose for at least 4 weeks before considering any increase 1
• If inadequate response after 4 weeks and tolerability is good, increase by 0.5 mg/kg/day every 2 weeks 1
• Maximum dose: 4 mg/kg/day (280 mg/day for this patient) 2, 1
• Expect clinical improvement within 2 weeks, with satisfactory control by 12-16 weeks 1
• Once controlled, taper to the lowest effective maintenance dose 1

For severe/crisis situations: Starting at 5 mg/kg/day (350 mg/day) is appropriate for rapid control, but this requires more intensive monitoring 2, 3

Critical Monitoring Parameters

First 8 Weeks (Intensive Phase)

Biweekly monitoring of: 2, 3

• Early morning resting blood pressure (more sensitive than creatinine for detecting nephrotoxicity)
• Serum creatinine and BUN
• These parameters are more practical than the FDA's comprehensive monthly panel in real-world practice

After 8 Weeks (Maintenance Phase)

Monthly monitoring of: 2

• Blood pressure
• Serum creatinine
• CBC, potassium, uric acid, lipids, magnesium, liver enzymes (per FDA labeling, though many clinicians focus primarily on BP and creatinine)

Managing Abnormalities

If creatinine rises >30% above baseline on two consecutive measurements:

• Reduce dose by 25-50% 1
• Recheck in 2 weeks
• If still elevated, discontinue cyclosporine 3

If blood pressure ≥140/90 mm Hg on two occasions:

• Reduce cyclosporine dose by 25-50% 2
• Preferred antihypertensives: Calcium channel blockers (isradipine, nifedipine, amlodipine) or beta-blockers 2, 3
• Avoid: Thiazide diuretics (enhance nephrotoxicity) and potassium-sparing diuretics (cyclosporine causes hyperkalemia) 2
• Discontinue if BP cannot be controlled despite dose reduction 2

Absolute Contraindications

2

• Renal insufficiency (baseline elevated creatinine)
• Uncontrolled hypertension
• History of systemic malignancy (excluding non-melanoma skin cancer)
• Prior extensive PUVA treatment (increased skin cancer risk)
• Uncontrolled infections
• Hypersensitivity to cyclosporine
• Live vaccinations during treatment

Special Considerations for This 70-Year-Old Patient

Age-related concerns: 3

• Elderly patients develop nephrotoxicity more readily due to underlying renal vascular disease
• Lower muscle mass may mask creatinine elevation—always compare to patient's own baseline, not population norms 3
• Consider starting at the lower end of dosing range (2.5 mg/kg/day)

Treatment Duration

Optimal approach: Intermittent short courses 2, 3

• Single courses up to 16 weeks are completely reversible regarding nephrotoxicity 3
• Courses of 3-6 months are safer than continuous therapy 2, 3
• Maximum continuous treatment: 1 year (2 years absolute maximum per British guidelines, but 1 year preferred) 2, 3
• Use topical therapy between courses to maintain remission 3

When to Stop Treatment

• Discontinue if no satisfactory response after 6 weeks at maximum tolerated dose 1
• Once controlled, taper and attempt discontinuation to assess ongoing need 1
• Relapse typically occurs 6-16 weeks after stopping 1

Alternative Treatment Options

For severe/recalcitrant psoriasis when cyclosporine is contraindicated or fails: 2

• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors)—now first-line for long-term management
• Methotrexate—can be combined with cyclosporine at doses ≤3 mg/kg/day 1
• Acitretin—non-immunosuppressive, safer for long-term use but slower onset (3-6 months) 2
• Phototherapy—but avoid if patient has had extensive prior PUVA

For specific variants: 2

• Erythrodermic/generalized pustular psoriasis: Cyclosporine is particularly effective (Strength B recommendation)
• Palmoplantar pustulosis: 89% response rate at 2.5 mg/kg/day 4

Critical Drug Interactions

Cyclosporine is metabolized by CYP3A4—numerous interactions exist: 2

• Avoid grapefruit juice (increases cyclosporine levels) 1
• Statins: Increased myopathy risk
• Calcium channel blockers: Verapamil and diltiazem increase cyclosporine levels; isradipine does not 2, 3
• Monitor closely with any CYP3A4 inhibitors or inducers

Common Pitfalls to Avoid

1. Don't monitor cyclosporine blood levels routinely—unnecessary at psoriasis doses unless on interacting medications or doses >3 mg/kg/day 2
2. Don't use population-based creatinine norms—always compare to patient's baseline 3
3. Don't ignore single morning BP readings—early morning resting BP is the most sensitive nephrotoxicity indicator 2
4. Don't continue beyond 1 year without compelling reason—structural kidney damage becomes irreversible 3
5. Don't abruptly discontinue—taper to preserve remission 5

2, 3, 1